IDEX Biometrics ASA - Private Placement successfully placed

05 Dec 2025 00:40 CET

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN OR THE UNITED
STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR
DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER
OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, Norway, 5 December 2025.

Reference is made to the stock exchange announcement published on 4 December
2025 by IDEX Biometrics ASA ("IDEX" or the "Company") regarding a contemplated
private placement (the "Private Placement") of new shares in the Company (the
"Offer Shares").

The Private Placement has been successfully completed, raising gross proceeds
to the Company of NOK 22 million, through the issuance of 7,333,333 Offer
Shares at a subscription price per Offer Share of NOK 3 (the "Offer Price").
The Private Placement was substantially oversubscribed.

The net proceeds from the Private Placement will be used to accelerate time to
profitability, working capital needs, as well as capital expenditures and
other general corporate purposes.

Anders Storbråten (privately and through Altea AS), Robert Keith, Morten
Opstad and Kjell-Arne Besseberg have, as pre-indicated, subscribed for NOK 6,6
million, NOK 6,4 million, NOK 0.5 million and NOK 0.15 million, respectively,
in the Private Placement.

The Private Placement was divided into two tranches. Tranche 1 ("Tranche 1")
consisted of 5,690,970 Offer Shares, and the share capital increase related to
Tranche 1 have been resolved by the board of directors (the "Board") pursuant
to an authorization granted by the Company's general meeting held on 14 August
2025 (the "Authorization"). Tranche 2 ("Tranche 2") will consist of 1,642,363
Offer Shares. The issuance of Offer Shares in Tranche 2 remains subject to
approval by an extraordinary general meeting, scheduled to be held at the end
of December or early January (the "EGM"). Anders Storbråten (privately and
through Altea AS) has agreed to be allocated Offer Shares in Tranche 2 of the
Private Placement.

The completion of Tranche 1 of the Private Placement is otherwise subject to
registration of the share capital increase pertaining to issue of the Offer
Shares in the Norwegian Register of Business Enterprises. The Tranche 2 of the
Private Placement is subject to completion of Tranche 1 and approval by the
EGM. The conditions described above are jointly referred to as the
"Conditions".

Completion of Tranche 1 is not conditional upon completion of Tranche 2, and
acquisition of shares in Tranche 1 will remain final and binding and cannot be
revoked or terminated by the respective applicants if Tranche 2 is not
completed. The Applicant acknowledges that Tranche 1 and Tranche 2 of the
Private Placement will be cancelled if the Conditions are not fulfilled and
that the Board reserves the right to cancel, and/or modify the terms of the
Private Placement, at any time and for any reason prior to delivery of the
Offer Shares in Tranche 1, without or on short notice. Neither the Company nor
any of its advisors will be liable for any losses if the Private Placement is
cancelled or modified, irrespective of the reason for such cancellation or
modification.

Following completion of Tranche 1, the Company's share capital will be NOK
62,600,677 divided into 62,600,677 shares, each with a par value of NOK 1.00.
Following completion of Tranche 2 of the Private Placement, and subject to EGM
approval, the Company's share capital will be NOK 64,243,040 divided into
64,243,040 shares, each with a par value of NOK 1.00.

The payment date for the Offer Shares in Tranche 1 will be 9 December 2025.
The Offer Shares will be delivered to investors and become tradable on the
Oslo Stock Exchange once the share capital increase has been duly registered
with the Norwegian Register of Business Enterprises. Such registration will
take place following receipt of the full subscription amount from all
participating investors. The Offer Shares in Tranche 1 are expected to be
delivered on or about 11 December 2025, subject to the timely payment by
investors. The settlement of Tranche 2 of the Private Placement is expected to
take place in early January 2025.

The Board has considered the contemplated Private Placement in light of the
equal treatment obligations under the Norwegian Securities Trading Act and
Oslo Børs' Circular no. 2/2014 and deems that the Private Placement is in
compliance with these requirements. The Board holds the view that it will be
in the common interest of the Company and its shareholders to raise equity
through a private placement, in view of the current market conditions and the
growth opportunities currently available to the Company. A private placement
enables the Company to raise capital in an efficient manner, and the Private
Placement is structured to ensure that a market-based subscription price is
achieved.

Taking into consideration that the Private Placement was carried out through a
publicly announced application period, and a market based subscription price
was achieved, the Board has concluded that a subsequent offering towards
existing shareholders is not necessary.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation (MAR) and is subject to the disclosure requirements
pursuant to MAR article 17 and section 5 -12 of the Norwegian Securities
Trading Act. This stock exchange release was published by Kjell-Arne
Besseberg, Chief Operating Officer, at the time and date stated above.

About IDEX Biometrics ASA

IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint
biometrics, offering authentication solutions across payments, access control,
and digital identity. Our solutions bring convenience, security, peace of mind
and seamless user experiences to the world. Built on patented and proprietary
sensor technologies, integrated circuit designs, and software, our biometric
solutions target card-based applications for payments and digital
authentication. As an industry-enabler we partner with leading card
manufacturers and technology companies to bring our solutions to market.

Important information:

This announcement is not and does not form a part of any offer to sell, or a
solicitation of an offer to purchase, any securities of the Company. The
distribution of this announcement and other information may be restricted by
law in certain jurisdictions. Copies of this announcement are not being made
and may not be distributed or sent into any jurisdiction in which such
distribution would be unlawful or would require registration or other
measures. Persons into whose possession this announcement or such other
information should come are required to inform themselves about and to observe
any such restrictions.

The securities referred to in this announcement have not been and will not be
registered under the U.S. Securities Act of 1933, as amended (the "Securities
Act"), and accordingly may not be offered or sold in the United States absent
registration or an applicable exemption from the registration requirements of
the Securities Act and in accordance with applicable U.S. state securities
laws. The Company does not intend to register any part of the offering or its
securities in the United States or to conduct a public offering of securities
in the United States. Any sale in the United States of the securities
mentioned in this announcement will be made solely to "qualified institutional
buyers" as defined in Rule 144A under the Securities Act.

In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
EU Prospectus Regulation, i.e., only to investors who can receive the offer
without an approved prospectus in such EEA Member State. The expression "EU
Prospectus Regulation" means Regulation 2017/1129 as amended together with any
applicable implementing measures in any Member State.

This communication is only being distributed to and is only directed at
persons in the United Kingdom that are (i) investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005, as amended (the "Order") or (ii) high net worth
entities, and other persons to whom this announcement may lawfully be
communicated, falling within Article 49(2)(a) to (d) of the Order (all such
persons together being referred to as "relevant persons"). This communication
must not be acted on or relied on by persons who are not relevant persons. Any
investment or investment activity to which this communication relates is
available only for relevant persons and will be engaged in only with relevant
persons. Persons distributing this communication must satisfy themselves that
it is lawful to do so.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as "believe", "expect",
"anticipate", "strategy", "intends", "estimate", "will", "may", "continue",
"should" and similar expressions. The forward-looking statements in this
release are based upon various assumptions, many of which are based, in turn,
upon further assumptions. Although the Company believes that these assumptions
were reasonable when made, these assumptions are inherently subject to
significant known and unknown risks, uncertainties, contingencies and other
important factors which are difficult or impossible to predict and are beyond
its control.

Actual events may differ significantly from any anticipated development due to
a number of factors, including without limitation, changes in investment
levels and need for the Company's services, changes in the general economic,
political and market conditions in the markets in which the Company operate,
the Company's ability to attract, retain and motivate qualified personnel,
changes in the Company's ability to engage in commercially acceptable
acquisitions and strategic investments, and changes in laws and regulation and
the potential impact of legal proceedings and actions. Such risks,
uncertainties, contingencies and other important factors could cause actual
events to differ materially from the expectations expressed or implied in this
release by such forward-looking statements. The Company does not provide any
guarantees that the assumptions underlying the forward-looking statements in
this announcement are free from errors nor does it accept any responsibility
for the future accuracy of the opinions expressed in this announcement or any
obligation to update or revise the statements in this announcement to reflect
subsequent events. You should not place undue reliance on the forward-looking
statements in this document.

The information, opinions and forward-looking statements contained in this
announcement speak only as at its date, and are subject to change without
notice. The Company does not undertake any obligation to review, update,
confirm, or to release publicly any revisions to any forward-looking
statements to reflect events that occur or circumstances that arise in
relation to the content of this announcement.

Neither the Company's advisors nor any of their affiliates make any
representation as to the accuracy or completeness of this announcement and
none of them accepts any responsibility for the contents of this announcement
or any matters referred to herein.

This announcement is for information purposes only and is not to be relied
upon in substitution for the exercise of independent judgment. It is not
intended as investment advice and under no circumstances is it to be used or
considered as an offer to sell, or a solicitation of an offer to buy any
securities or a recommendation to buy or sell any securities in the Company.
Neither the Company's advisors nor any of its affiliates accept any liability
arising from the use of this announcement.

Contacts
Anders Storbråten, CEO and CFO, Tel: +47 416 38 582
E-mail: ir@idexbiometrics.com

More information:
Access the news on Oslo Bors NewsWeb site

661324_IDEX Biometrics ASA - Private Placement successfully placed.pdf